Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer

Christopher Ryan, Dezheng Huo, Laurence M. Demers, Tomasz (Tom) Beer, Leo V. Lacerna

    Research output: Contribution to journalArticle

    101 Citations (Scopus)

    Abstract

    Purpose: Androgen deprivation therapy in patients with prostate cancer is associated with bone loss and an increased risk of fractures. Zoledronic acid protects against bone mineral density loss when initiated concurrently with androgen deprivation therapy. We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover. Materials and Methods: Patients with prostate cancer without bone metastases who had received androgen deprivation therapy for 12 months or less were randomized to 4 mg zoledronic acid or placebo intravenously every 3 months for 1 year. Patients were stratified according to androgen deprivation therapy duration (less than 6 vs 6 to 12 months). The primary end point was the change in femoral neck and lumbar spine bone mineral density in the 2 groups. The secondary end point was the change in serum bone specific alkaline phosphatase and urine N-telopeptide levels. Total hip bone mineral density was also measured. Results: The 120 patients with prostate cancer received zoledronic acid (61) or placebo (59). Compared with placebo, zoledronic acid increased femoral neck, total hip and lumbar spine bone mineral density yearly by 3.6% (p = 0.0004), 3.8% (p

    Original languageEnglish (US)
    Pages (from-to)972-978
    Number of pages7
    JournalJournal of Urology
    Volume176
    Issue number3
    DOIs
    StatePublished - Sep 2006

    Fingerprint

    zoledronic acid
    Bone Density
    Androgens
    Prostatic Neoplasms
    Femur Neck
    Placebos
    Spine
    Pelvic Bones
    Therapeutics
    Bone and Bones
    Bone Neoplasms
    Bone Remodeling
    Alkaline Phosphatase
    Hip
    Biomarkers
    Urine
    Neoplasm Metastasis

    Keywords

    • androgen antagonists
    • bone and bones
    • prostate
    • prostatic neoplasms
    • zoledronic acid

    ASJC Scopus subject areas

    • Urology

    Cite this

    Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. / Ryan, Christopher; Huo, Dezheng; Demers, Laurence M.; Beer, Tomasz (Tom); Lacerna, Leo V.

    In: Journal of Urology, Vol. 176, No. 3, 09.2006, p. 972-978.

    Research output: Contribution to journalArticle

    @article{e36874e88f4e4ce698b40c53603c6bc8,
    title = "Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer",
    abstract = "Purpose: Androgen deprivation therapy in patients with prostate cancer is associated with bone loss and an increased risk of fractures. Zoledronic acid protects against bone mineral density loss when initiated concurrently with androgen deprivation therapy. We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover. Materials and Methods: Patients with prostate cancer without bone metastases who had received androgen deprivation therapy for 12 months or less were randomized to 4 mg zoledronic acid or placebo intravenously every 3 months for 1 year. Patients were stratified according to androgen deprivation therapy duration (less than 6 vs 6 to 12 months). The primary end point was the change in femoral neck and lumbar spine bone mineral density in the 2 groups. The secondary end point was the change in serum bone specific alkaline phosphatase and urine N-telopeptide levels. Total hip bone mineral density was also measured. Results: The 120 patients with prostate cancer received zoledronic acid (61) or placebo (59). Compared with placebo, zoledronic acid increased femoral neck, total hip and lumbar spine bone mineral density yearly by 3.6{\%} (p = 0.0004), 3.8{\%} (p",
    keywords = "androgen antagonists, bone and bones, prostate, prostatic neoplasms, zoledronic acid",
    author = "Christopher Ryan and Dezheng Huo and Demers, {Laurence M.} and Beer, {Tomasz (Tom)} and Lacerna, {Leo V.}",
    year = "2006",
    month = "9",
    doi = "10.1016/j.juro.2006.04.078",
    language = "English (US)",
    volume = "176",
    pages = "972--978",
    journal = "Journal of Urology",
    issn = "0022-5347",
    publisher = "Elsevier Inc.",
    number = "3",

    }

    TY - JOUR

    T1 - Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer

    AU - Ryan, Christopher

    AU - Huo, Dezheng

    AU - Demers, Laurence M.

    AU - Beer, Tomasz (Tom)

    AU - Lacerna, Leo V.

    PY - 2006/9

    Y1 - 2006/9

    N2 - Purpose: Androgen deprivation therapy in patients with prostate cancer is associated with bone loss and an increased risk of fractures. Zoledronic acid protects against bone mineral density loss when initiated concurrently with androgen deprivation therapy. We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover. Materials and Methods: Patients with prostate cancer without bone metastases who had received androgen deprivation therapy for 12 months or less were randomized to 4 mg zoledronic acid or placebo intravenously every 3 months for 1 year. Patients were stratified according to androgen deprivation therapy duration (less than 6 vs 6 to 12 months). The primary end point was the change in femoral neck and lumbar spine bone mineral density in the 2 groups. The secondary end point was the change in serum bone specific alkaline phosphatase and urine N-telopeptide levels. Total hip bone mineral density was also measured. Results: The 120 patients with prostate cancer received zoledronic acid (61) or placebo (59). Compared with placebo, zoledronic acid increased femoral neck, total hip and lumbar spine bone mineral density yearly by 3.6% (p = 0.0004), 3.8% (p

    AB - Purpose: Androgen deprivation therapy in patients with prostate cancer is associated with bone loss and an increased risk of fractures. Zoledronic acid protects against bone mineral density loss when initiated concurrently with androgen deprivation therapy. We evaluated the effect of zoledronic acid initiated subsequent to androgen deprivation therapy on bone mineral density and biochemical markers of bone turnover. Materials and Methods: Patients with prostate cancer without bone metastases who had received androgen deprivation therapy for 12 months or less were randomized to 4 mg zoledronic acid or placebo intravenously every 3 months for 1 year. Patients were stratified according to androgen deprivation therapy duration (less than 6 vs 6 to 12 months). The primary end point was the change in femoral neck and lumbar spine bone mineral density in the 2 groups. The secondary end point was the change in serum bone specific alkaline phosphatase and urine N-telopeptide levels. Total hip bone mineral density was also measured. Results: The 120 patients with prostate cancer received zoledronic acid (61) or placebo (59). Compared with placebo, zoledronic acid increased femoral neck, total hip and lumbar spine bone mineral density yearly by 3.6% (p = 0.0004), 3.8% (p

    KW - androgen antagonists

    KW - bone and bones

    KW - prostate

    KW - prostatic neoplasms

    KW - zoledronic acid

    UR - http://www.scopus.com/inward/record.url?scp=33746555619&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33746555619&partnerID=8YFLogxK

    U2 - 10.1016/j.juro.2006.04.078

    DO - 10.1016/j.juro.2006.04.078

    M3 - Article

    C2 - 16890673

    AN - SCOPUS:33746555619

    VL - 176

    SP - 972

    EP - 978

    JO - Journal of Urology

    JF - Journal of Urology

    SN - 0022-5347

    IS - 3

    ER -